Mood stabilizers in pregnancy and lactation

Indian Journal of Psychiatry

Volumn 57, Issue , 2015, Pages 308-323

  Grover, Sandeep ^a   Avasthi, Ajit ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antipsychotics; bipolar disorder; mood stabilizers; pregnancy

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PSYCHOTROPIC AGENT; VALPROIC ACID; ALPRAZOLAM; AMISULPRIDE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; CLOZAPINE; DIAZEPAM; GABAPENTIN; LORAZEPAM; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; ZIPRASIDONE;

AUTISM; BIPOLAR DISORDER; CONGENITAL MALFORMATION; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; INTELLIGENCE QUOTIENT; LACTATION; PATIENT MONITORING; PREGNANCY; REVIEW; THIRD TRIMESTER PREGNANCY; BREAST FEEDING; DRUG EFFICACY; PUERPERIUM; RECURRENT DISEASE; RISK FACTOR; SECOND TRIMESTER PREGNANCY; UNPLANNED PREGNANCY;

EID: 84938327505     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.161498     Document Type: Review

References (216)

1. Sachs GS. Treatment?resistant bipolar depression. Psychiatr Clin North Am 1996;19:215-36.
2. Bowden CL. New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998;19:194-9.
3. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. J Clin Psychiatry 2002;63:146-51.
4. Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1999;60 Suppl 5:5-13.
5. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence?based response. Am J Psychiatry 2004;161:3-18.
6. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, et al. Management of bipolar disorder during pregnancy the postpartum period. Focus 2005;3:266-79.
7. Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002;63:284-7.
8. Jones I, Craddock N. Bipolar disorder and childbirth: The importance of recognising risk. Br J Psychiatry 2005;186:453-4.
9. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007;164:1817-24.
10. Pugh TF, Jerath BK, Schmidt WM, Reed RB. Rates of mental disease related to childbearing. N Engl J Med 1963;268:1224-8.
11. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987;150:662-73.
12. Terp IM, Mortensen PB. Post?partum psychoses. Clinical diagnoses and relative risk of admission after parturition. Br J Psychiatry 1998;172:521-6.
13. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-84.
14. Jefferson JW, Greist J, Ackermann D. Lithium Encyclopaedia for Clinical Practice. 2nd ed. Washington, DC: American Psychiatric Press; 1987. p. 504-25.
15. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: Weighing the risks and benefits. Can J Psychiatry 2002;47:426-36.
16. Cordero JF, Oakley GP Jr. Drug exposure during pregnancy: Some epidemiologic considerations. Clin Obstet Gynecol 1983;26:418-28.
17. Food and Drug Administration. Labeling and prescription drug advertising: Content and format for labeling for human prescription drugs. Fed Regist 1979;44:37434-67.
18. Key to FDA?in?use pregnancy ratings. In: Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data Production Co.; 1995. p. 2597.
19. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: Weighing the risks. J Clin Psychiatry 1998;59 Suppl 2:18-28.
20. Shepard TH, Brent RL, Friedman JM, Jones KL, Miller RK, Moore CA, et al. Update on new developments in the study of human teratogens. Teratology 2002;65:153-61.
21. American academy of paediatrics-section on breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129:e827-41.
22. Newton N, Newton M. Psychologic aspects of lactation. N Engl J Med 1967;277:1179-88.
23. Britton JR, Britton HL, Gronwaldt V. Breastfeeding, sensitivity, and attachment. Pediatrics 2006;118:e1436-43.
24. Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ, et al. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506.
25. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast?feeding. Am J Psychiatry 2001;158:1001-9.
26. Beath SV. Hepatic function and physiology in the newborn. Semin Neonatol 2003;8:337-46.
27. Nora JJ, Nora AH, Toews WH. Letter: Lithium, Ebstein's anomaly, and other congenital heart defects. Lancet 1974;2:594-5.
28. Schou M. Lithium treatment during pregnancy, delivery, and lactation: An update. J Clin Psychiatry 1990;51:410-3.
29. Weinstein MR. The international register of lithium babies. Drug Inf J 1976;10:94-100.
30. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-50.
31. Diav?Citrin O, Shechtman S, Tahover E, Finkel?Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: A prospective, comparative, observational study. Am J Psychiatry 2014;171:785-94.
32. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-3.
33. Grover S, Gupta N. Lithium?associated anencephaly. Can J Psychiatry 2005;50:185-6.
34. Tekin M, Ellison J. Oromandibular?limb hypogenesis spectrum and maternal lithium use. Clin Dysmorphol 2000;9:139-41.
35. Ellis DL, Guerra V, Pridjian G, Recto MR. Possible association between maternal lithium therapy and premature closure of the arterial duct. A case report. J Reprod Med 2013;58:181-4.
36. Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. Br Med J 1973;2:135-6.
37. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998;59 Suppl 6:57-64.
38. Yonkers KA, Little BB, March D. Lithium during pregnancy: Drug effects and therapeutic implications. CNS Drugs 1998;4:261-9.
39. Ananth J. Side effects on fetus and infant of psychotropic drug use during pregnancy. Int Pharmacopsychiatry 1976;11:246-60.
40. Schou M. What happened later to the lithium babies? A follow?up study of children born without malformations. Acta Psychiatr Scand 1976;54:193-7.
41. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry 2005;162:2162-70.
42. Woody JN, London WL, Wilbanks GD Jr. Lithium toxicity in a newborn. Pediatrics 1971;47:94-6.
43. Tunnessen WW Jr, Hertz CG. Toxic effects of lithium in newborn infants: A commentary. J Pediatr 1972;81:804-7.
44. Horton S, Tuerk A, Cook D, Cook J, Dhurjati P. Maximum recommended dosage of lithium for pregnant women based on a PBPK model for lithium absorption. Adv Bioinformatics 2012;2012:352729.
45. Skausig OB, Schou M. Breast feeding during lithium therapy. Ugeskr Laeger 1977;139:400-1.
46. van der Lugt NM, van de Maat JS, van Kamp IL, Knoppert?van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium?exposed pregnancies. Early Hum Dev 2012;88:375-8.
47. Yerby MS. Problems and management of the pregnant woman with epilepsy. Epilepsia 1987;28 Suppl 3:S29-36.
48. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-8.
49. Lindhout D, Omtzigt JG. Teratogenic effects of antiepileptic drugs: Implications for the management of epilepsy in women of childbearing age. Epilepsia 1994;35 Suppl 4:S19-28.
50. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937.
51. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, et al. The risk of spina bifida aperta after first?trimester exposure to valproate in a prenatal cohort. Neurology 1992;42:119-25.
52. Kennedy D, Koren G. Valproic acid use in psychiatry: Issues in treating women of reproductive age. J Psychiatry Neurosci 1998;23:223-8.
53. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-5.
54. Koch S, Lösche G, Jager?Roman E, Jakob S, Rating D, Deichl A, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992;42 4 Suppl 5:83-8.
55. Cole RL, Van Ross ER, Clayton?Smith J. Fibular aplasia in a child exposed to sodium valproate in pregnancy. Clin Dysmorphol 2009;18:37-9.
56. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-93.
57. Mawhinney E, Campbell J, Craig J, Russell A, Smithson W, Parsons L, et al. Valproate and the risk for congenital malformations: Is formulation and dosage regime important? Seizure 2012;21:215-8.
58. Vajda FJ, O'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology 2013;81:999-1003.
59. Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: Updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014;85:1029-34.
60. Jager?Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108:997-1004.
61. Felding I, Rane A. Congenital liver damage after treatment of mother with valproic acid and phenytoin? Acta Paediatr Scand 1984;73:565-8.
62. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993;69:288-91.
63. Majer RV, Green PJ. Neonatal afibrinogenaemia due to sodium valproate. Lancet 1987;2:740-1.
64. Meador KJ, Baker GA, Browning N, Clayton?Smith J, Combs?Cantrell DT, Cohen M, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597-605.
65. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton?Smith J, et al. Effects of fetal antiepileptic drug exposure: Outcomes at age 4.5 years. Neurology 2012;78:1207-14.
66. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton?Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study. Lancet Neurol 2013;12:244-52.
67. McVearry KM, Gaillard WD, VanMeter J, Meador KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav 2009;16:609-16.
68. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011;96:643-7.
69. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, et al. Child development following in utero exposure: Levetiracetam vs sodium valproate. Neurology 2011;76:383-9.
70. Nadebaum C, Anderson VA, Vajda F, Reutens DC, Barton S, Wood AG. Language skills of school?aged children prenatally exposed to antiepileptic drugs. Neurology 2011;76:719-26.
71. Bromley RL, Mawer G, Clayton?Smith J, Baker GA; Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008;71:1923-4.
72. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309:1696-703.
73. Gentile S. Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: A systematic review with regulatory repercussions. CNS Spectr 2014;19:305-15.
74. Piontek CM, Baab S, Peindl KS, Wisner KL. Serum valproate levels in 6 breastfeeding mother?infant pairs. J Clin Psychiatry 2000;61:170-2.
75. Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother?infant pairs. J Clin Psychopharmacol 1998;18:167-9.
76. Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, et al. Practice parameter update: Management issues for women with epilepsy-Focus on pregnancy (an evidence?based review): Vitamin K, folic acid, blood levels, and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:142-9.
77. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemical agents into human milk. Pediatrics 2001;108:776-89.
78. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-6.
79. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-7.
80. Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast?feeding. Eur J Pediatr 1990;150:136-8.
81. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose?dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17.
82. Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacother 1992;26:1563-5.
83. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner HA, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-70.
84. Gaily E, Kantola?Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
85. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: A review. J Clin Psychiatry 2000;61:79-90.
86. Eisenschenk S. Treatment with oxcarbazepine during pregnancy. Neurologist 2006;12:249-54.
87. Newport DJ, Stowe ZN, Viguera AC, Calamaras MR, Juric S, Knight B, et al. Lamotrigine in bipolar disorder: Efficacy during pregnancy. Bipolar Disord 2008;10:432-6.
88. Cunnington M, Tennis P; International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-60.
89. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70 (22 Pt 2):2152-8.
90. Dolk H, Jentink J, Loane M, Morris J, de Jong?van den Berg LT; EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71:714-22.
91. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 2013;170:1240-7.
92. Polepally AR, Pennell PB, Brundage RC, Stowe ZN, Newport DJ, Viguera AC, et al. Model?based lamotrigine clearance changes during pregnancy: Clinical implication. Ann Clin Transl Neurol 2014;1:99-106.
93. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long?term lamotrigine in epilepsy. Epilepsia 1997;38:881-6.
94. Rihtman T, Parush S, Ornoy A. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: Cognitive, motor, sensory and behavioral function. Reprod Toxicol 2013;41:115-25.
95. Rambeck B, Kurlemann G, Stodieck SR, May TW, Jürgens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 1997;51:481-4.
96. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: Pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000;41:709-13.
97. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: A case report. Epilepsia 1997;38:1039-41.
98. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast?feeding. Epilepsy Behav 2004;5:102-5.
99. Page?Sharp M, Kristensen JH, Hackett LP, Beran RG, Rampono J, Hale TW, et al. Transfer of lamotrigine into breast milk. Ann Pharmacother 2006;40:1470-1.
100. Newport DJ, Pennell PB, Calamaras MR, Ritchie JC, Newman M, Knight B, et al. Lamotrigine in breast milk and nursing infants: Determination of exposure. Pediatrics 2008;122:e223-31.
101. Medical Economics. Physician's Desk Reference. Montvale, NJ: Medical Economics; 2001.
102. Fadel RA, Sequeira RP, Abu?Hijleh MF, Obeidat M, Salem AH. Effect of prenatal administration of therapeutic doses of topiramate on ossification of ribs and vertebrae in rat fetuses. Rom J Morphol Embryol 2012;53:321-7.
103. Kwarta RF, Hulihan JF, Schmider J, Nye JS. Pregnancy outcomes in topiramate?treated women. Epilepsia 2006; 47 Suppl 4:119-204.
104. Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, et al. Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71:272-6.
105. Castilla?Puentes R, Ford L, Manera L, Kwarta RF Jr, Ascher S, Li Q. Topiramate monotherapy use in women with and without epilepsy: Pregnancy and neonatal outcomes. Epilepsy Res 2014;108:717-24.
106. Hernandez?Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9.
107. Mines D, Tennis P, Curkendall SM, Li DK, Peterson C, Andrews EB, et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf 2014;23:1017-25.
108. Hernandez?Diaz S, Mittendorf R, Smith CR, Hauser WA, Yerby M, Holmes LB, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014;123:21-8.
109. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 2014;261:579-88.
110. Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.e1-7.
111. Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: Does a fetal accumulation occur during pregnancy? Epilepsia 2005;46:1621-4.
112. Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, et al. Pregnancy outcomes following gabapentin use: Results of a prospective comparative cohort study. Neurology 2013;80:1565-70.
113. Goldstein DJ, Corbin LA, Fung MC. Olanzapine?exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol 2000;20:399-403.
114. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36:518-44.
115. Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: A review of data from global safety surveillance. BMC Pharmacol Toxicol 2013;14:38.
116. Levinson AJ, McKenna AK, Koren G, Zipursky RB. Pregnancy outcome in women receiving atypical antipsychotic drugs: A prospective, multicentre, controlled study. Schizophr Res 2003;60 Suppl 1:361.
117. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
118. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav?Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 2005;66:444-9.
119. Nagy A, Tényi T, Lénárd K, Herold R, Wilhelm F, Trixler M. Olanzapine and pregnancy. Orv Hetil 2001;142:137-8.
120. Kirchheiner J, Berghöfer A, Bolk?Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 2000;33:78-80.
121. Neumann NU, Frasch K. Olanzapine and pregnancy 2 case reports. Nervenarzt 2001;72:876-8.
122. Malek?Ahmadi P. Olanzapine in pregnancy. Ann Pharmacother 2001;35:1294-5.
123. Lim LM. Olanzapine and pregnancy. Aust N Z J Psychiatry 2001;35:856-7.
124. Mendhekar DN, War L, Sharma JB, Jiloha RC. Olanzapine and pregnancy. Pharmacopsychiatry 2002;35:122-3.
125. Littrell KH, Johnson CG, Peabody CD, Hilligoss N. Antipsychotics during pregnancy. Am J Psychiatry 2000;157:1342.
126. Vemuri MP, Rasgon NL. A case of olanzapine?induced gestational diabetes mellitus in the absence of weight gain. J Clin Psychiatry 2007;68:1989.
127. Aichhorn W, Yazdi K, Kralovec K, Steiner H, Whitworth S, Stuppaeck C. Olanzapine plasma concentration in a newborn. J Psychopharmacol 2008;22:923-4.
128. Friedman SH, Rosenthal MB. Treatment of perinatal delusional disorder: A case report. Int J Psychiatry Med 2003;33:391-4.
129. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry 2007;164:1214-20.
130. Dervaux A, Ichou P, Pierrot F, Devianne F, Bavoux F. Olanzapine and pregnancy [abstract]. Eur Psychiatry 2007;22:S110.
131. Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord 2006;8:400-4.
132. Kulkarni J, McCauley?Elsom K, Marston N, Gilbert H, Gurvich C, de Castella A, et al. Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy. Aust N Z J Psychiatry 2008;42:38-44.
133. Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry 2007;164:1759-60.
134. Spyropoulou AC, Zervas IM, Soldatos CR. Hip dysplasia following a case of olanzapine exposed pregnancy: A questionable association. Arch Womens Ment Health 2006;9:219-22.
135. Arora M, Praharaj SK. Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry 2006;21:345-6.
136. Prakash S, Chadda RK. Teratogenicity with olanzapine. Indian J Psychol Med 2014;36:91-3.
137. Gati A, Trixler M, Tenyi T. Pregnancy and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11 Suppl 3:S247.
138. Gardiner SJ, Kristensen JH, Begg EJ, Hackett LP, Wilson DA, Ilett KF, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast?fed infants. Am J Psychiatry 2003;160:1428-31.
139. Kasper SC, Mattiuz EL, Swanson SP, Chiu JA, Johnson JT, Garner CO. Determination of olanzapine in human breast milk by high?performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1999;726:203-9.
140. Goldstein DJ, Corbin LA, Whlreich K. Olanzapine use during breast feeding (abstract). Schizophr Res 2002;53 3 Suppl 1:185.
141. Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD. Olanzapine excretion in human breast milk: Estimation of infant exposure. Int J Neuropsychopharmacol 2002;5:243-7.
142. Ambresin G, Berney P, Schulz P, Bryois C. Olanzapine excretion into breast milk: A case report. J Clin Psychopharmacol 2004;24:93-5.
143. Gilad O, Merlob P, Stahl B, Klinger G. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed Med 2011;6:55-8.
144. Rosengarten H, Quartermain D. Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats. Pharmacol Biochem Behav 2002;72:575-9.
145. MacKay FJ, Wilton GL, Pearce SN, Freemantle SH, Mann RD. The safety of risperidone: A post?marketing study on 7684 patients. Hum Psychopharmacol Clin Exp 1998;13:423-8.
146. Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry 2002;63:76-7.
147. Kato R, Sato J, Suzuki H. Anesthesia for cesarean section in a parturient taking risperidone and haloperidol. Masui 2005;54:301-3.
148. Kim SW, Kim KM, Kim JM, Shin IS, Shin HY, Yang SJ, et al. Use of long?acting injectable risperidone before and throughout pregnancy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:543-5.
149. Dabbert D, Heinze M. Follow?up of a pregnancy with risperidone microspheres. Pharmacopsychiatry 2006;39:235.
150. Grover S, Avasthi A. Risperidone in pregnancy: A case of oligohydramnios. German J Psychiatry 2004;7:56-7.
151. Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: Pregnancy and neonatal outcomes. Drug Saf 2007;30:247-64.
152. McCauley?Elsom K, Kulkarni J. Managing psychosis in pregnancy. Aust N Z J Psychiatry 2007;41:289-92.
153. Ghaffari N, Dossett E, Lee RH, Aghajanian P. Antipsychotics leading to neuroleptic malignant syndrome in pregnancy. Obstet Gynecol 2012;119 (2 Pt 2):436-8.
154. Hill RC, McIvor RJ, Wojnar?Horton RE, Hackett LP, Ilett KF. Risperidone distribution and excretion into human milk: Case report and estimated infant exposure during breast?feeding. J Clin Psychopharmacol 2000;20:285-6.
155. Ilett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ. Transfer of risperidone and 9?hydroxyrisperidone into human milk. Ann Pharmacother 2004;38:273-6.
156. Aichhorn W, Stuppaeck C, Whitworth AB. Risperidone and breast?feeding. J Psychopharmacol 2005;19:211-3.
157. Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: Results of a post?marketing surveillance study on 1728 patients in England. J Psychopharmacol 2007;21:392-9.
158. Balke LD. Quetiapine is Effective in the Treatment of Bipolar Affective Disorder during Pregnancy. Poster Session Presented at: 7th World Congress of Biological Psychiatry; July 1-6, 2001; Berlin, Germany.
159. Texnyi T, Trixler M, Kerestes Z. Quetiapine and pregnancy [letter]. Am J Psychiatry 2002;159:674.
160. Pace A, D'Agostino F. Quetiapine in pregnancy: A case report. G Ital Ostet Ginecol 2003;25:381-5.
161. Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. Am J Psychiatry 2004;161:1715-6.
162. Gentile S. Quetiapine?fluvoxamine combination during pregnancy and while breastfeeding. Arch Womens Ment Health 2006;9:158-9.
163. Kruninger U, Meltzer V, Hiemke C, Herpich S. Pregnancy and lactation under treatment with quetiapine. Psychiatr Prax 2007;34 Suppl: 75-6.
164. Cabuk D, Sayin A, Derinöz O, Biri A. Quetiapine use for the treatment of manic episode during pregnancy. Arch Womens Ment Health 2007;10:235-6.
165. Kaya DF, Sayin A, Biri A. Quetiapine use in manic episode during pregnancy: A case report. 1 Eur Psychiatry 2007;22:S166.
166. Frayne J, Nguyen T, Kohan R, De Felice N, Rampono J.The comprehensive management of pregnant women with major mood disorders: A case study involving phenelzine, lithium, and quetiapine. Arch Womens Ment Health 2014;17:73-5.
167. Grover S, Madan R. Successful use of quetiapine in two successive pregnancies. J Neuropsychiatry Clin Neurosci 2012;24:E38.
168. Tényi T, Nagy Á, Herold R, Fekete S. Extended release quetiapine fumarate and pregnancy. Neuropsychopharmacol Hung 2013;15:49-50.
169. Rampono J, Kristensen JH, Ilett KF, Hackett LP, Kohan R. Quetiapine and breast feeding. Ann Pharmacother 2007;41:711-4.
170. Peitl MV, Petric D, Peitl V. Ziprasidone as a possible cause of cleft palate in a newborn. Psychiatr Danub 2010;22:117-9.
171. Werremeyer A. Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. Am J Psychiatry 2009;166:1298.
172. Aripiprazole Prescribing Information. Bristol?Myers Squibb Pharmaceuticals/ Otsuka Pharmaceutical Co Ltd.; 2003.
173. Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord 2006;8:299-300.
174. Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother 2006;40:575.
175. Doulgeraki G, Karadima D, Kalogiratos D, Grekiotis A, Magoula K. Pregnancy, aripiprazole and psychotherapy. Eur Psychiatry 2007;22:S206.
176. Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health 2008;11:249-50.
177. Wichman CL. Atypical antipsychotic use in pregnancy: A retrospective review. Arch Womens Ment Health 2009;12:53-7.
178. Lutz UC, Hiemke C, Wiatr G, Farger G, Arand J, Wildgruber D. Aripiprazole in pregnancy and lactation: A case report. J Clin Psychopharmacol 2010;30:204-5.
179. Gentile S, Tofani S, Bellantuono C. Aripiprazole and pregnancy: A case report and literature review. J Clin Psychopharmacol 2011;31:531-2.
180. Watanabe N, Kasahara M, Sugibayashi R, Nakamura T, Nakajima K, Watanabe O, et al. Perinatal use of aripiprazole: A case report. J Clin Psychopharmacol 2011;31:377-9.
181. Nguyen T, Teoh S, Hackett LP, Ilett K. Placental transfer of aripiprazole. Aust N Z J Psychiatry 2011;45:500-1.
182. Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: A case report. Pharmacopsychiatry 2012;45:299-300.
183. Derganc M, Savs AP. The use of aripiprazole in pregnancy: A case report. Abstract P002 at the 21st European Congress of Psychiatry EPA, April 6-9, 2013; Nice, France.
184. Windhager E, Kim SW, Saria A, Zauner K, Amminger PG, Klier CM. Perinatal use of aripiprazole: Plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol 2014;34:637-41.
185. Waldman MD, Safferman AZ. Pregnancy and clozapine. Am J Psychiatry 1993;150:168-9.
186. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994;151:945.
187. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998;49:1081-3.
188. Di Michele V, Ramenghi L, Sabatino G. Clozapine and lorazepam administration in pregnancy. Eur Psychiatry 1996;11:214.
189. Stoner SC, Sommi RW Jr, Marken PA, Anya I, Vaughn J. Clozapine use in two full?term pregnancies. J Clin Psychiatry 1997;58:364-5.
190. Tényi T, Trixler M, Vereczkey G, Dorka A. Use of clozapine during pregnancy. Orv Hetil 1994;135:1967-9.
191. Gupta N, Grover S. Safety of clozapine in 2 successive pregnancies. Can J Psychiatry 2004;49:863.
192. Sethi S. Clozapine in pregnancy. Indian J Psychiatry 2006;48:196-7.
193. Dev V, Knapp P. The side effects and safety of clozapine. Rev Contemp Pharmacother 1995;6:197-208.
194. Yogev Y, Ben?Haroush A, Kaplan B. Maternal clozapine treatment and decreased fetal heart rate variability. Int J Gynaecol Obstet 2002;79:259-60.
195. Coston AL, Hoffmann P, Equy V, Sergent F, Vidal C. Fetal heart rate variability and clozapine treatment. Gynecol Obstet Fertil 2012;40:549-52.
196. Moreno?Bruna MD, de Montgolfier I, Chabaud M, Dommergues M. Case report: Neonatal delayed peristalsis after in?utero exposure to clozapine. Arch Pediatr 2012;19:913-6.
197. Mendhekar DN. Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation. J Neuropsychiatry Clin Neurosci 2007;19:196-7.
198. Baker RW, Chengappa KN. Gastroesophageal reflux as a possible result of clozapine treatment. J Clin Psychiatry 1998;59:257.
199. Mendhekar DN, Sharma JB, Srivastava PK, War L. Clozapine and pregnancy. J Clin Psychiatry 2003;64:850.
200. Klys M, Rojek S, Rzepecka?Wozniak E. Neonatal death following clozapine self?poisoning in late pregnancy: An unusual case report. Forensic Sci Int 2007;171:e5-10.
201. Novikova N, Chitnis M, Linder V, Hofmeyr GJ. Atypical antipsychotic (clozapine) self?poisoning in late pregnancy presenting with absent fetal heart rate variability without acidosis and delayed peristalsis in the newborn baby: A case report. Aust N Z J Obstet Gynaecol 2009;49:442-4.
202. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39-49.
203. Saxén I, Saxén L. Letter: Association between maternal intake of diazepam and oral clefts. Lancet 1975;2:498.
204. Entman SS, Vaughn WK. Lack of relation of oral clefts to diazepam use in pregnancy. N Engl J Med 1984;310:1121-2.
205. Czeizel A. Letter: Diazepam, phenytoin, and aetiology of cleft lip and/or cleft palate. Lancet 1976;1:810.
206. Saxén I. Epidemiology of cleft lip and palate. An attempt to rule out chance correlations. Br J Prev Soc Med 1975;29:103-10.
207. Czeizel A, Lendvay A. In utero exposure to benzodiazepines [letter]. Lancet 1987;1:628.
208. Shiono PH, Mills JL. Oral clefts and diazepam use during pregnancy. N Engl J Med 1984;311:919-20.
209. Czeizel A. Endpoints of reproductive dysfunction in an experimental epidemiological model: Self?poisoned pregnant women. In: Chambers PL, Gehring P, Sakai F, editors. New Concepts and Developments in Toxicology. Amsterdam: Elsevier; 1986.
210. Czeizel A, Pázsy A, Pusztai J, Nagy M. Aetiological monitor of congenital abnormalities: A case?control surveillance system. Acta Paediatr Hung 1983;24:91-9.
211. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-20.
212. Curtis V. Women are not the same as men: Specific clinical issues for female patients with bipolar disorder. Bipolar Disord 2005;7 Suppl 1:16-24.
213. Delgado?Escueta AV, Janz D. Consensus guidelines: Preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992;42 4 Suppl 5:149-60.
214. Weinstein MR. Lithium treatment of women during pregnancy and in the post?delivery period. In: Johnson FN, editor. Handbook of Lithum theraphy. Park Pren: Baltimore University; 1980. p. 421-9.
215. Stewart DE, Klompenhouwer JL, Kendell RE, van Hulst AM. Prophylactic lithium in puerperal psychosis. The experience of three centres. Br J Psychiatry 1991;158:393-7.
216. Cohen LS, Sichel DA, Robertson LM, Heckscher E, Rosenbaum JF. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995;152:1641-5.